Bioavailability of Orally Ingested Vitamin C

Healthy Clinical Trial

— ABBA  

Official title:

Investigating the Oral Bioavailability of Vitamin C Administered Using Phosphycell™ Technology - a Phosphatidylcholine-lipid Encapsulation Technology.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05183880
• Other study ID #: 21-10-20-B-01
• Status: Recruiting
• Phase: N/A
• Start date: November 26, 2021
• Est. completion date: November 26, 2023

Study information

• Verified date: May 2022
• Source: University of Exeter
• Contact: Tom Jameson
• Phone: +44 (0) 1392 722157
• Email: T.Jameson[@]exeter.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if crystalline vitamin C supplementation can acutely increase skeletal muscle vitamin C concentrations and if this can be potentiated by administering vitamin C using Phosphycell™ Technology - a phosphatidylcholine-lipid encapsulation technology.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: November 26, 2023
• Est. primary completion date: November 26, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Body mass index (BMI) 18.5 - 30 kg/m2
• Age 18 - 40
• Non-smoker

Exclusion Criteria:

• Body mass index (BMI) < 18.5 or > 30 kg/m2
• Age < 18 or > 40
• Smoking
• Cardiovascular disease
• Hypertension (= 140/90 mmHg)
• Metabolic disease
• Medications known to affect vitamin C metabolism
• A known vitamin C deficiency
• Less than 2 hours per week of physical activity or following a structured exercise training program.
• Routine use of vitamin supplements

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• Phosphatidylcholine-lipid encapsulated vitamin C
Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
• Crystalline vitamin C
Ingesting 1000 mg of vitamin C in crystalline form

Locations

Country	Name	City	State
United Kingdom	Sport and Health Sciences	Exeter	Devon

Sponsors (1)

Lead Sponsor	Collaborator
University of Exeter

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Skeletal muscle vitamin C concentrations	Skeletal muscle vitamin C concentrations 6 hours after vitamin C ingestion will be measured using HPLC and compared to baseline	6 hours after vitamin C ingestion
Primary	Skeletal muscle vitamin C concentrations	Skeletal muscle vitamin C concentrations 12 hours after vitamin C ingestion will be measured using HPLC and compared to baseline and 6 hours after vitamin C ingestion	12 hours after vitamin C ingestion
Secondary	Blood plasma vitamin C concentrations	Blood plasma vitamin C concentrations will be measured using HPLC during the 24 hour post vitamin C ingestion period	24 hours after vitamin C ingestion
Secondary	White blood cell vitamin C concentrations	White blood cell vitamin C concentrations will be measured 6 hours after vitamin C ingestion using HPLC and compared to baseline	6 hours after vitamin C ingestion
Secondary	White blood cell vitamin C concentrations	White blood cell vitamin C concentrations will be measured 24 hours after vitamin C ingestion using HPLC and compared to baseline and 3 hours post vitamin C ingestion	24 hours after vitamin C ingestion
Secondary	Cardiovascular function	Cardiovascular function will be measuring using a finger plethysmograph during the 24 hour post vitamin C ingestion period	24 hours after vitamin C ingestion